Replies to post #4450 on GTC Biotherapeutics (fka GTCB)

[mblimon]

Does it really matter, when another company has a big head start? Being in Phase III already Genentech/BIIB may expand the market substantially before the (better) transgenic product comes to market.

So it will only mean a larger market to be attacked, isn't it?

[gym gravity]

could be confidence (on GTCB/LFBs) part, that ADCC is going to be a big deal.

[icebrg]

I’m somewhat surprised by today’s CD20 announce-
ment because it takes guts to go head-to-head against
Genentech and BIIB, who are co-developing a second-
generation CD20 mAb called Ocrelizumab:

Further, there is a Genmab/GSK CD20 mAb in phase III.